How a longtime Peninsula biotech company’s stomach cancer drug moved closer to the finish line

Results this month from the company's mid-stage clinical trial sent its stock soaring and helped it raise $174 million. But it took nine years, layoffs, CEO changes and serendipity to get there.

Click to view original post